WHO ICTRP trial
The efficacy and safety of Tofacitinib combined with mycophenolate mofetil…
ChiCTR2500114368 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2500114368 |
|---|---|
| Public title | The efficacy and safety of Tofacitinib combined with mycophenolate mofetil versus tofacitinib in patients with glucocorticoid resistant ICIs-related myocarditis: a multicenter, randomized, controlled clinical study |
| Scientific title | The efficacy and safety of Tofacitinib combined with mycophenolate mofetil versus tofacitinib in patients with glucocorticoid resistant ICIs-related myocarditis: a multicenter, randomized, controlled clinical study |
| Primary sponsor | Zhongshan Hospital, Fudan University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Countries | China |
| Conditions | Immune checkpoint inhibitor-associated myocarditis |
| Interventions | Treatment Group:Tofaciib and Mycophenolate Mofetil;Control Group:Tofaciib |
| Registration date | Dec 11, 2025 |
| Target size | Treatment Group:58;Control Group:58 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: